Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 10 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing the launch of a biosimilar product, Denosumab, aimed at protecting bone health in cancer patients. The biosimilar, named 'Zyrifa', is intended to reduce skeletal-related events in patients with various types of cancer. Dr. Sharvil P. Patel, the Managing Director, emphasized the importance of this medication in improving patient mobility and quality of life during cancer treatment.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone health in cancer patients".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases